BIT225, an orally administered, small molecule drug demonstrated good antiviral activity against HCV.
The drug specifically targets the p7 protein, a viral protein essential to virus production and replication.
During the course of the trial, patients receiving BIT225 in combination with interferon and ribavirin showed better reductions in HCV levels than patients receiving standard of care treatment alone.
BIT225 also showed good results in terms of tolerability and efficacy, the company said.